- Ilan Sobel, CEO of BioHarvest sat down with Dave Jackson to share BioHarvest’s vision of bringing the power of plants to the people
- BioHarvest Sciences is a biotechnology company that has built a BioFarming technology platform that grows plant cells in their natural structure in proprietary bioreactors
- The company is estimating 2022 revenue to be between US$5M-$7M
- The company is targeting 1H 2022 for the first sales of its cannabis product
- Shares in BioHarvest Sciences Inc. (BHSC) is currently trading at C$0.355 per share
Ilan Sobel, CEO of BioHarvest Sciences sat down with Dave Jackson to share BioHarvest’s vision and explain what makes the company unique.
BioHarvest Sciences is a biotechnology company that has built a platform technology that can provide therapeutic solutions for people’s health & wellness.
BioHarvest’s proprietary BioFarming platform technology creates the opportunity to expand the company’s product offering both vertically and horizontally and we look forward to bringing innovative product solutions to the market. We also plan to start R&D development on a new vertical in 2022 where our platform technology can provide a disruptive solution for unmet consumer needs.
For the above reasons we will continue to make significant investments in this platform that would solidify BHSC as a Biotech innovator and yield healthy long-term growth and profitability,” remarked Ilan Sobel, CEO of BioHarvest.
As previously reported, the company is estimating 2022 revenue to be between US$5M-$7M, representing a growth of 2.5X-3.5X over 2021
“I look forward to an outstanding year with significant revenue growth and major technological achievements. The 2022 projected revenue guidance demonstrates the growing demand for our VINIA® product and the anticipation for our cannabis solutions.
Looking forward, BioHarvest plans to continue to invest heavily in R&D and in the building of manufacturing capacity for its Cannabis vertical in Israel and abroad.
BioHarvest’s ambition is to become a multi-billion-dollar biotech company.
Shares in BioHarvest Sciences Inc. (BHSC) are currently trading at C$0.355 per share.
